Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Hypoxia-induced complement component 3 promotes aggressive tumor growth in the glioblastoma microenvironment
Rebecca Rosberg, Karolina I. Smolag, Jonas Sjölund, Elinn Johansson, Christina Bergelin, Julia Wahldén, Vasiliki Pantazopoulou, Crister Ceberg, Kristian Pietras, Anna M. Blom, Alexander Pietras
Rebecca Rosberg, Karolina I. Smolag, Jonas Sjölund, Elinn Johansson, Christina Bergelin, Julia Wahldén, Vasiliki Pantazopoulou, Crister Ceberg, Kristian Pietras, Anna M. Blom, Alexander Pietras
View: Text | PDF
Research Article Oncology

Hypoxia-induced complement component 3 promotes aggressive tumor growth in the glioblastoma microenvironment

  • Text
  • PDF
Abstract

Glioblastoma (GBM) is the most aggressive form of glioma with a high rate of relapse despite intensive treatment. Tumor recurrence is tightly linked to radio-resistance, which in turn is associated with hypoxia. Here, we discovered a strong link between hypoxia and local complement signaling using publicly available bulk, single-cell, and spatially resolved transcriptomic data from patients with GBM. Complement component 3 (C3) and the receptor C3AR1 were both associated with aggressive disease and shorter survival in human glioma. In a genetically engineered mouse model of GBM, we found C3 specifically in hypoxic tumor areas. In vitro, we found an oxygen level–dependent increase in C3 and C3AR1 expression in response to hypoxia in several GBM and stromal cell types. C3a induced M2 polarization of cultured microglia and macrophages in a C3aR-dependent fashion. Targeting C3aR using the antagonist SB290157 prolonged survival of glioma-bearing mice both alone and in combination with radiotherapy while reducing the number of M2-polarized macrophages. Our findings establish a strong link between hypoxia and complement pathways in GBM and support a role of hypoxia-induced C3a/C3aR signaling as a contributor to glioma aggressiveness by regulating macrophage polarization.

Authors

Rebecca Rosberg, Karolina I. Smolag, Jonas Sjölund, Elinn Johansson, Christina Bergelin, Julia Wahldén, Vasiliki Pantazopoulou, Crister Ceberg, Kristian Pietras, Anna M. Blom, Alexander Pietras

×

Figure 4

C3AR1 is associated with aggressive GBM.

Options: View larger image (or click on image) Download as PowerPoint

C3AR1 is associated with aggressive GBM.
(A) C3AR1 expression of Pan-Ca...
(A) C3AR1 expression of Pan-Cancer TCGA data of common cancer types (n = 33). (B) C3AR1 expression in relation to glioma grade as analyzed in TCGA data. (C) C3AR1 expression in IDHwt glioma compared with IDHmut with or without 1p/19q codeletion (Tukey post hoc test) as analyzed in TCGA data. (D) C3AR1 expression in GBM compared with nontumor as analyzed in TCGA data. (E) Kaplan-Meier curve showing survival of patients with glioma with either high (red) or low (blue) C3AR1 expression based on TCGA data. (F) Kaplan-Meier curve showing survival of IDHwt GBM with high (red) or low (blue) C3AR1 expression based on TCGA data. (G) UMAP displaying C3AR1 expression in single-cell RNA-Seq data from 26 independent data sets compiled in GBmap (25). (H) C3AR1 expression of malignant cells divided into C3AR1+ (3.1%) or C3AR1– (96.9%) cells. (I) GSEA of the C3AR1-expressing malignant cells. Red bars indicate significant Benjamini-Hochberg adjusted P values (Padj < 0.05). (J) Log-fraction plot of a combination of independent extreme limiting dilution sphere formation assays (n = 4) of U3082MG glioma cells treated with SB290157. *P < 0.05, **P < 0.01, or ***P< 0,001. One-way ANOVA (B and C), or unpaired t test (D) (in case of comparison between 2 groups) with Tukey post hoc test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts